Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b…
Sight preserved in the patient’s only seeing eye through timely intervention at Manipal Hospital Broadway
KOLKATA, India, May 26, 2026 /PRNewswire/ -- An elderly man in his sixties…
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colore
This positive CHMP opinion is based on results from the Phase 3…
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X…
BC-led clinical trial points to safer care for critically ill patients
NEW WESTMINSTER, British Columbia, May 19, 2026 (GLOBE NEWSWIRE) -- A BC-led…
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
LONDON, May 13, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader…
BioNTech and DualityBios Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint…
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts…
AgelessRx 2026: Longevity Telehealth Platform Overview Treatments, Pricing, Compounded Medications, and What Prospective Patients Should Know
Ann Arbor, MI, March 13, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article…
Novartis Cosentyx receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Cosentyx is the only IL-17A inhibitor approved for this population, and the…
